ACM
BBOT

Aisling Capital Management’s BridgeBio Oncology BBOT Stock Holding History

Aisling Capital Management’s Portfolio BBOT Stock Details BBOT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.11M Buy
1,018,018
+453,393
+80% +$4.87M 1.91% 5
2025
Q4 		$7.07M Hold
564,625
– – 1.48% 6
2025
Q3 		$6.54M Buy
+564,625
New +$5.88M 1.43% 8

Other funds holding BBOT

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Aisling Capital Management's BBOT Position: Q1 2026 in Review

Aisling Capital Management increased its BridgeBio Oncology (BBOT) stake by 80% in Q1 2026, buying an estimated $4.87M and bringing the position to 1,018,018 shares worth $9.11M. The position accounts for 1.91% of the portfolio, ranked #5.

Aisling Capital Management first reported a position in BBOT in Q3 2025 and has held it in 3 quarters since. 67 funds tracked by Wall St. Rank hold BBOT as of Q1 2026.

  • Aisling Capital Management held 1,018,018 shares of BridgeBio Oncology worth $9.11M as of Q1 2026.
  • Aisling Capital Management bought 453,393 BridgeBio Oncology shares in Q1 2026, an estimated $4.87M.
  • BridgeBio Oncology made up 1.91% of Aisling Capital Management's portfolio in Q1 2026, its #5 holding.
  • Aisling Capital Management first reported a position in BridgeBio Oncology in Q3 2025 and has held it in 3 quarters since.
  • 67 funds tracked by Wall St. Rank held BridgeBio Oncology as of Q1 2026.

Based on Aisling Capital Management's 13F filing for Q1 2026, filed 5 May 2026.